This website uses cookies. By continuing you are agreeing to our privacy policy.

J. Robert Coleman, PhD

Research Awards Nationwide Recipient (2013-2015)

State University of New York, Farmingdale, NY
New Streptococcus Pneumonia Vaccine Would Protect Against All Strains
Biomedical Research Grant
Funded in Partnership with support from the Mary Fuller Russell Research Fund

Streptococcus pneumonia (SP) is the leading cause of bacterial pneumonia in the United States and worldwide. There are two current vaccines for SP—one for adults and one for children. However, each is limited as neither vaccine protects against all 92 strains of SP that have emerged and caused disease in susceptible populations. Dr. Coleman and his team have begun to genetically redesign genes shared by all 92 serotypes to construct a "universal" vaccine to produce a weakened strain that over-expresses "protective" proteins. Some in the pneumococcal field have suggested that a whole-cell/live vaccine approach may be the most promising avenue to achieve 92-serotype protection and their project pursues this approach.

Red button with telephone
Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
Red button of two hand prints
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

Button of turquoise LUNG FORCE swirl

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.